Abstract 198P
Background
Women with breast cancer with impaired immunity develop life-threatening clinical disease. Findings of tumor-associated lymphocytes in tumor specimens are explicit evidence of immunologic sensitivity to this. Despite several treatment modalities, the majority of patients eventually relapse. However, immunotherapy – a new promising modality for treatment - has been advocated to command disease progress. Cancer immunoediting provided insights that the immune system has both immune surveillance and tumor promotion effects during cancer development. Anti-tumor immune response requires involvement of both CD4+ and CD8+ T cells. Thus, for better understanding the roles of CD4+ CD8 and regulatory T cells in pathogenesis and progression of breast cancer, the following study was designed to be conducted in clinical patients with breast cancer. 1-To determine expression of FOXP3 CD25, CD4, CD8 before therapy in blood, and tumor tissue. 2-Impact of surgery and chemotherapy on immunological status of tumour in breast cancer patients.
Methods
This was a prospective observational pilot study. Patients: N=30, locally advanced and metastatic breast cancer patients receiving chemotherapy as first modality of treatment (NACT group). N=30, early breast cancer patients receiving surgery as first modality of treatment (Upfront surgery). Control: N=30, Sex matched group undergoing surgery for benign breast disease.
Results
In the pre-treatment group lower expression of CD4 and higher CD8 and Tregs were found as the disease progresses. After upfront surgery CD4 counts increase with decrease of CD8 and Tregs cells. There was no change in CD4 in the control after surgery with positive correlation in CD8 and Tregs. Higher CD4 counts with lower CD8 and Tregs were found in patients after NACT.
Conclusions
T-cell subgroups in breast cancer patients undergo dynamic, significant changes during surgery and chemotherapy. Comprehensive analysis of characteristic T cell repertoire in breast cancer has depicted a landscape of possibilities of developing a blood-based therapeutic or preventive (vaccine) modality to enhance the armamentarium against this cancer.
Legal entity responsible for the study
AIIMS.
Funding
AIIMS New Delhi.
Disclosure
The author declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract